Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Other Non Operating Income (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Other Non Operating Income for 14 consecutive years, with -$8.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income fell 5.13% year-over-year to -$8.9 million, compared with a TTM value of $93000.0 through Dec 2025, up 101.21%, and an annual FY2025 reading of $93000.0, down 98.43% over the prior year.
  • Other Non Operating Income was -$8.9 million for Q4 2025 at Fate Therapeutics, down from $2.5 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $15.8 million in Q2 2022 and bottomed at -$8.9 million in Q4 2025.
  • Average Other Non Operating Income over 5 years is $1.7 million, with a median of $742000.0 recorded in 2021.
  • The sharpest move saw Other Non Operating Income plummeted 4726.09% in 2024, then soared 1084.14% in 2025.
  • Year by year, Other Non Operating Income stood at $11.3 million in 2021, then fell by 28.8% to $8.1 million in 2022, then tumbled by 97.72% to $184000.0 in 2023, then tumbled by 4726.09% to -$8.5 million in 2024, then fell by 5.13% to -$8.9 million in 2025.
  • Business Quant data shows Other Non Operating Income for FATE at -$8.9 million in Q4 2025, $2.5 million in Q3 2025, and $2.9 million in Q2 2025.